Payment overview · 2025
General Payments
$1,082.48
59 reported records · 13 companies
Healthcare provider profile · identity verified
Amy Jordan Eubanks, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BREMEN, GA · NPI 1962441493
Verified facts
What the public records show
CMS Open Payments records show Amy Jordan Eubanks, M.D. received $1,082.48 in general payments during 2025 across 59 reported records.
PFIZER INC. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Movantik, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Gemtesa by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $180.01 | 16.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.24 | 16.3% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.93 | 12.7% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.77 | 11.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $99.42 | 9.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.97 | 8.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.99 | 7.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.67 | 5.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.53 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.37 | 3.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.66 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.54 | 1.5% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $14.38 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,082.48 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $180.01 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $180.01 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.73 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $126.77 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $99.42 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.97 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $80.99 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.67 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.51 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.11 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 201 | exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
201 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
303 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 686 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 578 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 137 |
| Gabapentin | Gabapentin | 417 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 118 |
| Lisinopril | Lisinopril | 353 | 96 |
| Famotidine | Famotidine | 352 | 110 |
| Fluticasone Propionate | Fluticasone Propionate | 346 | 134 |
| Losartan Potassium | Losartan Potassium | 343 | 99 |
| Trazodone Hcl | Trazodone Hcl | 337 | 98 |
| Omeprazole | Omeprazole | 333 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 99 |
| Montelukast Sodium | Montelukast Sodium | 326 | 88 |
| Ezetimibe | Ezetimibe | 314 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 307 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 89 |
| Ozempic | Semaglutide | 303 | 48 |
| Ondansetron Odt | Ondansetron | 267 | 74 |
| Tramadol Hcl | Tramadol Hcl | 260 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 249 | 56 |
| Fluoxetine Hcl | Fluoxetine Hcl | 243 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 61 |
| Eliquis | Apixaban | 232 | 45 |
| Potassium Chloride | Potassium Chloride | 224 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 38 |
| Furosemide | Furosemide | 213 | 77 |
| Mounjaro | Tirzepatide | 201 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 58 |
| Metformin Hcl Er | Metformin Hcl | 200 | 57 |
| Carvedilol | Carvedilol | 178 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 24 |
| Prednisone | Prednisone | 175 | 114 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 172 | 40 |
| Meloxicam | Meloxicam | 164 | 54 |
| Allopurinol | Allopurinol | 152 | 46 |
| Buspirone Hcl | Buspirone Hcl | 148 | 46 |
| Methylprednisolone | Methylprednisolone | 145 | 115 |
| Azelastine Hcl | Azelastine Hcl | 144 | 61 |
| Myrbetriq | Mirabegron | 144 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 39 |
| Bupropion Xl | Bupropion Hcl | 131 | 30 |
| Sertraline Hcl | Sertraline Hcl | 126 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 37 |
| Clonazepam | Clonazepam | 123 | 21 |
| Azithromycin | Azithromycin | 118 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 32 |
| Repatha Sureclick | Evolocumab | 118 | 32 |
| Estradiol | Estradiol | 117 | 40 |
| Lorazepam | Lorazepam | 116 | 29 |
| Pregabalin | Pregabalin | 116 | 38 |
| Simvastatin | Simvastatin | 115 | 27 |
| Jardiance | Empagliflozin | 112 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 28 |
| Methocarbamol | Methocarbamol | 104 | 41 |
| Metformin Hcl | Metformin Hcl | 103 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 28 |
| Glimepiride | Glimepiride | 92 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 22 |
| Alprazolam | Alprazolam | 90 | 15 |
| Temazepam | Temazepam | 90 | 19 |
| Sucralfate | Sucralfate | 85 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 58 |
| Promethazine Hcl | Promethazine Hcl | 76 | 23 |
| Mirtazapine | Mirtazapine | 73 | 16 |
| Linzess | Linaclotide | 71 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 69 | 26 |
| Lubiprostone | Lubiprostone | 69 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 22 |
| Ketoconazole | Ketoconazole | 66 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 30 |
| Memantine Hcl | Memantine Hcl | 65 | 16 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Aripiprazole | Aripiprazole | 63 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 46 |
| Colestipol Hcl | Colestipol Hcl | 58 | 24 |
| Rizatriptan | Rizatriptan Benzoate | 57 | 16 |
| Fluconazole | Fluconazole | 54 | 33 |
| Gemtesa | Vibegron | 54 | 12 |
| Cephalexin | Cephalexin | 51 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 16 |
| Celecoxib | Celecoxib | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 25 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Atenolol | Atenolol | 47 | 12 |
| Ibuprofen | Ibuprofen | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 44 | suppressed |
| Nystatin | Nystatin | 44 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 26 |
| Clonidine Hcl | Clonidine Hcl | 40 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 39 | 11 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Valacyclovir | Valacyclovir Hcl | 38 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 18 |
| Varenicline Tartrate | Varenicline Tartrate | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 20 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Zaleplon | Zaleplon | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,082.48 · 59 records | PFIZER INC. | Auvelity, CAPLYTA, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, MOVANTIK, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error